Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Earnings for Amicus Therapeutics, Inc. (FOLD)
Earnings in 2023 (TTM): $-150,101,000
According to Amicus Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-150,101,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Amicus Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-150,101,000 | $-151,584,000 |
| 2022 | $-242,039,000 | $-236,568,000 |
| 2021 | $-241,554,000 | $-250,460,000 |
| 2020 | $-274,254,000 | $-276,852,000 |
| 2019 | $-355,910,000 | $-356,388,000 |
| 2018 | $-349,089,000 | $-348,995,000 |
| 2017 | $-449,121,000 | $-284,002,000 |
| 2016 | $-203,781,000 | $-200,042,000 |
| 2015 | $-132,118,000 | $-132,118,000 |
| 2014 | $-70,039,000 | $-68,926,000 |
| 2013 | $-63,145,000 | $-59,633,000 |
| 2012 | $-52,030,000 | $-48,785,000 |
| 2011 | $-48,041,000 | $-44,412,000 |
| 2010 | $-56,075,000 | $-54,936,000 |
| 2009 | $-6,567,000 | $-6,567,000 |
| 2008 | $-39,355,000 | $-39,355,000 |
| 2007 | $-41,167,000 | $-41,167,000 |
| 2006 | $-46,344,910 | $-46,344,910 |
| 2005 | $-20,584,086 | $-19,972,289 |
| 2004 | $ | $-8,807,102 |
| 2003 | $-6,768,000 | $-6,768,000 |